April 2 (Reuters) - Novo Nordisk A/S NOVOb.CO:
NOVO NORDISK: WEGOVY PILL 25 MG SHOWED GREATER MEAN WEIGHT LOSS VERSUS. ORFORGLIPRON 36 MG IN POPULATION-ADJUSTED INDIRECT TREATMENT COMPARISON
NOVO NORDISK: POPULATION-ADJUSTED INDIRECT TREATMENT COMPARISON USES DATA FROM OASIS 4 & ATTAIN-1 CLINICAL TRIALS
NOVO NORDISK: IN SEPARATE PATIENT PREFERENCE STUDY, 84% FAVORED WEGOVY PILL 25MG-LIKE TREATMENT PROFILE VERSUS. ORFORGLIPRON-LIKE PROFILE
NOVO NORDISK: ORFORGLIPRON 36MG TREATMENT HAD ABOUT 14 TIMES HIGHER DISCONTINUATION ODDS DUE TO GASTROINTESTINAL ADVERSE EVENTS VERSUS WEGOVY PILL 25MG
Further company coverage: [NOVOb.CO]